StockTipsArenaBeta

BUY Dr. Lal Path Labs Ltd. — IDBI Capital

BUYDr. Lal Path Labs Ltd.

byIDBI CapitalHorizon: NA (inferred Swing (≤2wk))9 Sept 2026via IDBI Capital Research Calls Telegram

Entry₹1,935Stated
Target₹2,050
Total upside +5.94%
Stop loss₹1,881-2.79% risk
CMP₹1,915.5Just now
Active-1.01%+7.02%upside left 14d left
Follow IDBI Capital for new calls(28% target hit, 191 closed calls)Get alertsWatch LALPATHLAB for new buy/sell callsGet alertsSee 204 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 9 Sept, 11:34 am IST
2 supporting1 opposing
Supports the BUY call (2)

Dr. Lal Ventures Private Limited, a wholly-owned subsidiary, has completed the subscription of a 30% stake in Neuome Technologies Private Limited. Neuome now becomes an associate of the company.

BSE · Company Update·27 Aug · 2w ago

(opens in new tab)

3 advisors have active short-term BUY calls on this stock

Advisor consensus · adjacent horizon·19 Aug · 3w ago

Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (1)

MACD below its signal line — bearish momentum

Technicals · macd·9 Sept · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.